Mortimer Ian's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Dec 3, 2025
- Accession no.
- 0001193125-25-307211
- Filed
- Dec 3, 2025
- Trade date
- Nov 28, 2025
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $4.37K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mortimer IanCIK 0001619961 | Director, Officer (PRESIDENT & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Shares | SSaleDisposed | −97 | $45.01 | −$4,365.97 | 31,205 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.